Generic Drug Stocks Gain Attention as New Growth Drivers Reshape the Sector

Sandoz, Teva Pharmaceutical Industries and Viatris are drawing investor attention as the generic drug industry moves beyond traditional low-cost medicines and focuses more heavily on biosimilars, complex generics and specialty treatments.

The original Zacks report highlighted three generic drug stocks to watch: Sandoz, Teva and Viatris, noting that new growth drivers are emerging across the medical generic drugs space. Zacks’ article summary points to biosimilars, complex generics and specialty drugs as the key themes reshaping the sector.

Why Generic Drug Companies Are Changing Strategy

For years, generic drugmakers relied on selling cheaper versions of branded medicines after patents expired. That model still matters, but it has become harder. Pricing pressure, competition, supply-chain costs and regulatory requirements have reduced profit margins across many basic generic products.

As a result, leading companies are trying to build stronger businesses through products that are more difficult to copy. These include biosimilars, which are lower-cost versions of complex biologic medicines, and complex generics, which often require advanced manufacturing, delivery systems or regulatory expertise.

Sandoz: Biosimilars Become a Major Growth Engine

Sandoz is one of the best-known names in generics and biosimilars. The company reported that 2025 net sales grew 5% to $11.1 billion, with biosimilars accounting for 30% of total sales. Its pipeline includes 27 biosimilar medicines and around 400 generic medicines in development, targeting large reference medicine markets.

This gives Sandoz a clear position in the global shift toward affordable biologic alternatives. As healthcare systems look for ways to reduce medicine costs, biosimilars may become more important in areas such as immunology, oncology and bone health.

Teva: Branded Medicines Support the Turnaround

Teva is also changing its growth story. The company’s “Pivot to Growth” strategy focuses on innovative medicines, biosimilars and complex generics. Teva reported 2025 revenue of $17.3 billion, up 4% year over year, while key innovative brands generated more than $3 billion in revenue.

Recent results show why investors are watching Teva closely. Reuters reported that Teva beat first-quarter profit expectations as branded medicines helped offset pressure in generics. Products such as Austedo, Ajovy and Uzedy have become important parts of the company’s growth plan.

Viatris: Pipeline and Capital Returns Remain in Focus

Viatris is another major player in the sector. The company reported full-year 2025 revenue of $14.3 billion and said it met or exceeded key financial guidance. It also returned more than $1 billion to shareholders in 2025 and expects several regulatory decisions and pipeline milestones in 2026.

Viatris has been working to reshape its business by focusing on sustainable growth, complex products, eye care opportunities and disciplined capital allocation. This strategy may help the company reduce dependence on older products while improving long-term earnings stability.

Industry Outlook

The generic drug industry is not without risk. Pricing pressure remains a major challenge, and companies must invest heavily in manufacturing quality, regulatory approvals and product development. However, the shift toward biosimilars and complex medicines may create stronger growth opportunities than traditional plain-vanilla generics.

For investors, the key question is whether these companies can turn their pipelines into steady revenue growth. Sandoz offers strong biosimilar exposure, Teva is showing progress with branded medicines and Viatris is working to unlock value through pipeline milestones and shareholder returns.

Conclusion

Sandoz, Teva and Viatris are becoming more than ordinary generic drugmakers. Their future growth may depend on biosimilars, specialty medicines, complex generics and better portfolio management. While risks remain, these three companies are worth watching as the generic drug industry enters a new phase of development.

#GenericDrugs #PharmaStocks #Biosimilars #HealthcareInvesting #SlimScan #GrowthStocks #CANSLIM